Callan Family Office LLC Buys New Shares in Ingevity Corporation $NGVT

Posted by Stanley Muller on Aug 25th, 2026

Callan Family Office LLC bought a new stake in shares of Ingevity Corporation (NYSE:NGVT – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 14,498 shares of the company’s stock, valued at approximately $1,083,000.

Other large investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Ingevity in the second quarter valued at $400,545,000. Millennium Management LLC boosted its position in shares of Ingevity by 1.3% during the 3rd quarter. Millennium Management LLC now owns 1,189,524 shares of the company’s stock worth $65,650,000 after purchasing an additional 15,562 shares in the last quarter. Royce & Associates LP grew its stake in shares of Ingevity by 7.7% in the 4th quarter. Royce & Associates LP now owns 1,111,158 shares of the company’s stock valued at $65,758,000 after buying an additional 79,059 shares during the period. Brown Advisory Inc. grew its stake in shares of Ingevity by 15.4% in the 4th quarter. Brown Advisory Inc. now owns 1,040,944 shares of the company’s stock valued at $61,603,000 after buying an additional 138,859 shares during the period. Finally, Simcoe Capital Management LLC increased its position in Ingevity by 9.4% in the 4th quarter. Simcoe Capital Management LLC now owns 1,020,945 shares of the company’s stock valued at $60,420,000 after buying an additional 87,490 shares in the last quarter. Institutional investors and hedge funds own 91.59% of the company’s stock.

Analyst Upgrades and Downgrades

NGVT has been the topic of a number of research reports. Weiss Ratings raised Ingevity from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, July 31st. Wall Street Zen downgraded shares of Ingevity from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 1st. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $80.00.

Get Our Latest Report on NGVT

Ingevity Stock Down 2.0%

NGVT stock opened at $68.88 on Tuesday. The stock has a fifty day moving average of $73.77 and a 200-day moving average of $71.86. Ingevity Corporation has a fifty-two week low of $45.85 and a fifty-two week high of $79.29. The company has a market capitalization of $2.37 billion, a price-to-earnings ratio of 46.86 and a beta of 1.16. The company has a debt-to-equity ratio of 22.52, a quick ratio of 1.15 and a current ratio of 1.61.

Ingevity (NYSE:NGVT – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported $1.74 EPS for the quarter, beating analysts’ consensus estimates of $1.33 by $0.41. The company had revenue of $314.10 million for the quarter, compared to analysts’ expectations of $312.20 million. Ingevity had a net margin of 4.65% and a return on equity of 284.70%. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. As a group, equities research analysts predict that Ingevity Corporation will post 5.4 earnings per share for the current year.

Insider Buying and Selling at Ingevity

In related news, SVP Terrance M. Dyer sold 496 shares of Ingevity stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $68.49, for a total transaction of $33,971.04. Following the completion of the sale, the senior vice president owned 7,202 shares of the company’s stock, valued at approximately $493,264.98. This trade represents a 6.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Ryan C. Fisher sold 2,709 shares of Ingevity stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $73.72, for a total value of $199,707.48. Following the sale, the senior vice president owned 15,722 shares of the company’s stock, valued at approximately $1,159,025.84. This trade represents a 14.70% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 18,297 shares of company stock valued at $1,381,452 in the last three months. Company insiders own 0.88% of the company’s stock.

Ingevity Profile

(Free Report)

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.